Company intelligence / Profile preview
Merus
Utrecht, Utrecht, Netherlandsmerus.nl ↗
- Ownership
- Public · MRUS
- Employees
- ~321
- Development stage
- Phase 3
01
Overview
Summary of current clinical results highlights encouraging single-agent activity of petosemtamab in head & neck cancers as well as combination therapy potential[1][3][4].
- Therapeutic areas
- Oncology
- Modalities
- Full-length human bispecific antibodies (Biclonics®)Trispecific antibodies (Triclonics®)Antibody-drug conjugates (ADClonics®) derived from Biclonics®
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Betta Pharmaceuticals Co. Ltd. for development/commercialization rights in China to MCLA‑129[4]Eli Lilly and Company[5]Ono Pharmaceutical Co., Ltd.[5]
Beyond the preview
Go deeper on Merus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Merus.